Zacks.com on MSN4d
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...
lifesciencesweden.se6d
AZ gets approval for drug targeting rare disease –it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
Daily10d
AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...
Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Declines By 10.0%
AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 37,100 shares ...
biopharma-reporter12d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up ...
Pharmaceutical Technology12d
EC approves AstraZeneca’s Fasenra for EGPA treatment
The European Commission (EC) has approved AstraZeneca ‘s Fasenra (benralizumab) as an add-on therapy for adults with ...
EuropaWire12d
Qatar Airways Leads in Digital Innovation, Adopting Thales’ Groundbreaking FlytEDGE Inflight Entertainment System for A321 NX Fleet
Qatar Airways has partnered with Thales to equip its A321 NX fleet with FlytEDGE, the first cloud-native inflight ...
Pharmabiz12d
European Union approves AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
EuropaWire13d
AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...
AstraZeneca’s Fasenra approved in EU for EGPA
Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or ...
PharmiWeb13d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...